The role of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in the assessment of fibrosis in children with chronic hepatitis C.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
17
11
2021
accepted:
08
06
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
At present, noninvasive fibrosis markers are not available for the assessment of liver fibrosis in children with chronic hepatitis C. Sixty-three children with chronic hepatitis C were included. Changes in Wisteria floribunda agglutinin-positive Mac-2 binding protein (M2BPGi) levels were evaluated in l3 of 27 treatment-naive patients during the natural course of disease (median 4, range 3-6 years). Changes during treatment were evaluated in 27 of 36 patients for 4 (2-9) years of posttreatment follow-up. There were significant differences in the levels of M2BPGi between control group and HCV F0 group (P = 0.002) and between control group and HCV F1 group (P < 0.001). Receiver operating characteristic curve analysis showed that to discriminate stage F1 fibrosis from F0, the cut-off value was 0.95 for M2BPGi with a sensitivity of 52%, specificity of 90%, and area under the curve of 0.687. A substantial decrease in M2BPGi levels by treatment was shown from 0.98 ± 0.57 at pretreatment to 0.42 ± 0.15 at posttreatment (P < 0.001) in the 27 treated patients. Our study shows new findings that M2BPGi may be useful to predict the presence of a mild degree of fibrosis in children with chronic hepatitis C, and such mild fibrosis may be quickly resolved by treatment.
Identifiants
pubmed: 35778417
doi: 10.1038/s41598-022-14553-8
pii: 10.1038/s41598-022-14553-8
pmc: PMC9249794
doi:
Substances chimiques
Membrane Glycoproteins
0
Plant Lectins
0
Receptors, N-Acetylglucosamine
0
wisteria lectin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11205Informations de copyright
© 2022. The Author(s).
Références
Eur J Gastroenterol Hepatol. 2010 Aug;22(8):946-51
pubmed: 20110820
J Hepatol. 2007 Oct;47(4):598-607
pubmed: 17692984
J Gastroenterol. 2017 Feb;52(2):245-252
pubmed: 27349650
J Gastroenterol Hepatol. 2017 Dec;32(12):1922-1930
pubmed: 28406534
Hepatology. 2014 Nov;60(5):1563-70
pubmed: 25042054
Hepatology. 2005 Oct;42(4):962-73
pubmed: 16149085
J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):443-50
pubmed: 18030211
Sci Rep. 2013;3:1065
pubmed: 23323209
World J Gastroenterol. 2015 Nov 7;21(41):11567-83
pubmed: 26556987
Hepatology. 1997 Sep;26(3):771-5
pubmed: 9303511
Hepatology. 2002 Nov;36(5 Suppl 1):S161-72
pubmed: 12407590
J Hepatol. 2010 Dec;53(6):1013-21
pubmed: 20850886
Hepatol Res. 2021 Mar;51(3):277-283
pubmed: 33393720
J Hepatol. 2012 Aug;57(2):281-7
pubmed: 22521355
Aliment Pharmacol Ther. 2016 Jan;43(1):114-24
pubmed: 26503582
J Gastroenterol. 2015 Jan;50(1):76-84
pubmed: 24603981
Proteomics Clin Appl. 2013 Oct;7(9-10):642-7
pubmed: 23640794
J Gastroenterol. 2018 Mar;53(3):419-426
pubmed: 28567493
Hepatol Res. 2015 Nov;45(11):1083-90
pubmed: 25565570
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Gastroenterology. 2005 Feb;128(2):343-50
pubmed: 15685546
J Gastroenterol. 2018 Jul;53(7):819-826
pubmed: 29318378
Gut. 2020 Jul;69(7):1343-1352
pubmed: 32066623
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
J Viral Hepat. 2013 Jan;20(1):72-6
pubmed: 23231087